VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
LOVELAND, Colo.--(BUSINESS WIRE)--Antech™, a global veterinary diagnostics, technology and imaging company, today announced the launch of two new vector-borne disease diagnostics in their expanding portfolio: enhanced Accuplex™, a reference lab canine vector-borne disease (CVBD) screening test which now detects seven pathogens, and an enhanced vector-borne disease PCR profile, the veterinary industry’s most comprehensive PCR panel of its kind. Based on current testing data disseminated by the C
AUSTIN, Texas--(BUSINESS WIRE)---- $AMD #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai™ platform, with a direct comparison to gold-standard wet-lab methods. The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and cos
TORONTO--(BUSINESS WIRE)--Intrepid Labs’ Valiant platform uses AI and robotics to cut drug formulation timelines from months to days.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2025 Business Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD. The patent, which is expected to provide exclusivity until 2041, includes cla
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the CureDuchenne FUTURES National Conference, taking place in San Antonio, TX, from May 22 to 25. Satellos Co-founder and CEO Frank Gleeson will participate in the “New Therapeutic Approaches” session on Sat., May 24 from 1:30-2:30 p.m. CT. Event and registrati
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. “With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients a
VANCOUVER, British Columbia & COLUMBUS, Ohio--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 million investment in Armatus Bio, a biotechnology company developing next-generation vectorized RNAi therapeutics for neuromuscular diseases. The investment will support ARM-201, Armatus Bio’s AAV-delivered microRNA therapy designed to silence the expression of DUX4, the toxic p
TORONTO--(BUSINESS WIRE)-- #ARDS--Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2025 American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, at the Moscone Center, San Francisco, CA. Vasomune’s lead drug candidate AV-001 is a first-in-class fully syn
